These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 1346801

  • 21. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
    Biswas G, Khadwal A, Arora B, Bhagwat R, Banavali SD, Nair CN, Pai SK, Kurkure PA, Parikh PM.
    Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC, von Rohr A, Ratschiller D, Schmitz SF, Egger T, Sonderegger T, Herrmann R, Kroner T, Zulian GB, Cavalli F, Fey MF, Cerny T.
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Laurencet F, Ballabeni P, Rufener B, Hess U, Cerny T, Fey M, Luthi JM, Plancherel C, Zulian GB, Swiss Group for Clinical Research (SAKK).
    Acta Haematol; 2007 Mar; 117(1):40-7. PubMed ID: 17095858
    [Abstract] [Full Text] [Related]

  • 28. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.
    Hochster HS, Kim KM, Green MD, Mann RB, Neiman RS, Oken MM, Cassileth PA, Stott P, Ritch P, O'Connell MJ.
    J Clin Oncol; 1992 Jan; 10(1):28-32. PubMed ID: 1727921
    [Abstract] [Full Text] [Related]

  • 29. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
    Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA, Cancer and Leukemia Group B.
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):793-8. PubMed ID: 18648813
    [Abstract] [Full Text] [Related]

  • 30. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
    Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A.
    Leuk Lymphoma; 2006 Sep; 47(9):1818-21. PubMed ID: 17064994
    [Abstract] [Full Text] [Related]

  • 31. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ, Chow KU, Karakas T, Jäger E, Mezger J, von Grünhagen U, Schalk KP, Burkhard O, Hansmann ML, Ritzel H, Bergmann L, Hoelzer D, Mitrou PS.
    Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
    [Abstract] [Full Text] [Related]

  • 32. 2-CdA in the treatment of hairy cell leukaemia.
    Abhyankar D, Bajpai S, Saikia T, Gopal R, Nair CN, Advani SH.
    J Assoc Physicians India; 2001 Aug; 49():785-7. PubMed ID: 11837464
    [Abstract] [Full Text] [Related]

  • 33. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
    Hainsworth JD.
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections.
    Juliusson G, Liliemark J.
    Blood; 1992 Feb 15; 79(4):888-94. PubMed ID: 1346578
    [Abstract] [Full Text] [Related]

  • 36. The purine analogs--a therapeutic beauty contest.
    Cheson BD.
    J Clin Oncol; 1992 Mar 15; 10(3):352-5. PubMed ID: 1346799
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases.
    Robak T, Błasińska-Morawiec M, Krykowski E, Hellmann A, Lewandowski K, Dmoszyńska A, Adamczyk-Cioch M, Kazimierczak M, Trepińska E, Dwilewicz-Trojaczek M, Kuratowska Z, Skotnicki AB, Nowak WS, Zdziarska B, Urasiński I.
    Eur J Haematol; 1997 Oct 15; 59(4):216-20. PubMed ID: 9338619
    [Abstract] [Full Text] [Related]

  • 39. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.
    Piro LD, Carrera CJ, Beutler E, Carson DA.
    Blood; 1988 Sep 15; 72(3):1069-73. PubMed ID: 2901280
    [Abstract] [Full Text] [Related]

  • 40. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
    Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M.
    J Clin Oncol; 2005 Oct 20; 23(30):7565-73. PubMed ID: 16186600
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.